Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share (CTNM)

Historical Holders from Q2 2024 to Q4 2025

Type / Class
Equity / Class A Common Stock, $0.001 par value per share
Symbol
CTNM on Nasdaq
Shares outstanding
21,500,623
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
17,478,081
Total reported value
$205,365,503
% of total 13F portfolios
0%
Share change
+3,621,729
Value change
+$48,626,440
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
61
Price from insider filings
$11.13
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share (CTNM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% $8,106,040 2,122,000 RA Capital Management, L.P. 18 Jul 2025
FRANKLIN RESOURCES INC 7.7% -13% $19,453,682 -$508,531 1,655,548 -2.5% Franklin Resources, Inc. 30 Sep 2025
SECTORAL ASSET MANAGEMENT INC 5% $6,142,078 950,786 Jerome G. Pfund 31 Dec 2024
PERCEPTIVE ADVISORS LLC 3.2% -54% $7,029,834 -$7,454,718 699,486 -51% Perceptive Advisors LLC 30 Jun 2025
As of 30 Sep 2025, Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share (CTNM) has 61 institutional shareholders filing 13F forms. They hold 17,478,081 shares. of 21,500,623 outstanding shares (81%) .

Top 25 institutional shareholders own 78% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 9.9% 2,122,000 0.31% $24,933,500
JOHNSON & JOHNSON 9.2% 1,979,173 0% 4.6% $23,255,283
SUVRETTA CAPITAL MANAGEMENT, LLC 8% 1,720,000 0% 0.61% $20,210,000
FRANKLIN RESOURCES INC 7.7% 1,655,548 -2.5% 0% $19,452,689
VANGUARD GROUP INC 4.5% 964,232 +30% 0% $11,329,726
Balyasny Asset Management L.P. 4.4% 951,320 0.02% $11,178,010
FMR LLC 3.8% 814,871 -3.4% 0% $9,574,734
SECTORAL ASSET MANAGEMENT INC 3.7% 800,787 0% 5.8% $9,409,247
PERCEPTIVE ADVISORS LLC 3.3% 714,592 +2.2% 0.25% $8,396,456
HHLR ADVISORS, LTD. 3.1% 669,337 0% 0.19% $7,864,710
MILLENNIUM MANAGEMENT LLC 3% 646,022 +388% 0.01% $7,590,758
RED TREE MANAGEMENT, LLC 3% 638,158 0% 9% $7,498,357
SAMSARA BIOCAPITAL, LLC 2.7% 571,142 -3% 0.88% $6,710,919
Versant Venture Management, LLC 2.5% 542,628 0% 3% $6,375,879
Point72 Asset Management, L.P. 1.7% 367,645 -5.4% 0.01% $4,319,828
BlackRock, Inc. 1.5% 322,031 +95% 0% $3,783,865
GEODE CAPITAL MANAGEMENT, LLC 0.98% 211,050 +196% 0% $2,481,056
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.95% 204,119 +914% 0% $2,398,398
MARSHALL WACE, LLP 0.9% 193,491 +575% 0% $2,273,522
SILVERARC CAPITAL MANAGEMENT, LLC 0.77% 166,161 0.28% $1,952,392
Casdin Capital, LLC 0.69% 148,333 0% 0.15% $1,742,913
Eversept Partners, LP 0.63% 134,619 0.12% $1,581,773
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.51% 110,178 +323% 0% $1,294,592
MORGAN STANLEY 0.43% 92,995 +0.1% 0% $1,092,692
ADAR1 Capital Management, LLC 0.36% 77,961 -53% 0.09% $916,042

Institutional Holders of Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share (CTNM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 0 $0 -$447 0
2025 Q3 17,478,081 $205,365,503 +$48,626,440 1,175% 61
2025 Q2 13,856,430 $55,287,652 -$6,405,457 397% 68
2025 Q1 15,121,377 $105,551,838 -$10,223,175 698% 62
2024 Q4 15,761,089 $230,901,883 +$21,882,709 1,465% 60
2024 Q3 13,597,553 $256,178,767 +$9,075,038 1,914% 51
2024 Q2 13,016,510 $229,220,087 +$229,145,473 1,761% 49